2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.11B.04 Differential Durable Responses in Intrathoracic Versus Overall Lesions of Non-Small Cell Lung Cancer Treated with Immunotherapy

EP.11B.04 Differential Durable Responses in Intrathoracic Versus Overall Lesions of Non-Small Cell Lung Cancer Treated with Immunotherapy

Back to course

Pdf Summary

The study investigates the differential tumor response to immunotherapy in non-small cell lung cancer (NSCLC) between intrathoracic and extrathoracic lesions, highlighting the role of tumor heterogeneity. It aims to assess the concordance of response rates for intrathoracic versus overall lesions in NSCLC patients undergoing immunotherapy and identifies key clinical factors associated with durable response (DR).<br /><br />The study found that the concordance of tumor response between overall and intrathoracic lesions was high at 80.8%. A key finding was that patients with intrathoracic DR showed a median progression-free survival (mPFS) and median overall survival (mOS) of 12.2 and 30.7 months, respectively, as compared to those with non-DR, whose mPFS and mOS were 3.8 and 9.4 months. For the overall group, patients with DR had an mPFS and mOS of 14.3 and 35.7 months, respectively, compared to non-DR patients, with mPFS and mOS of 2.7 and 10.5 months.<br /><br />A lower baseline platelet count was significantly associated with a DR in intrathoracic lesions, suggesting it could be a clinical indicator of response. However, factors like tumor mutational burden, PD-L1 status, or treatment regimen did not show significant differences between durable responders and non-responders.<br /><br />The study concludes that the durable response in NSCLC patients treated with immunotherapy may significantly impact survival outcomes. The median duration of treatment was notably longer for durable responders compared to non-responders in both overall and intrathoracic lesions.<br /><br />These findings underscore the importance of considering lesion location and specific clinical factors when evaluating NSCLC patient responses to immunotherapy, offering potential pathways for optimizing treatment strategies. The results were presented at the 2024 World Conference on Lung Cancer (WCLC).

Asset Subtitle

Young Kwang Chae

Meta Tag

Speaker Young Kwang Chae

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

NSCLC

immunotherapy

tumor response

intrathoracic lesions

extrathoracic lesions

tumor heterogeneity

durable response

progression-free survival

overall survival

clinical factors